Valuation: Sutro Biopharma, Inc.

Market Cap 151M 135M 124M 113M 211M 14.33B 215M 1.48B 595M 7.53B 566M 554M 23.77B P/E 2026 *
-1.12x
P/E 2027 * -1.39x
Enterprise Value 151M 135M 124M 113M 211M 14.33B 215M 1.48B 595M 7.53B 566M 554M 23.77B EV / Sales 2026 *
2.87x
EV / Sales 2027 * 4.83x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * -
1 day-0.44%
1 week-2.47%
Current month-43.51%
1 month-43.51%
3 months-63.34%
6 months-75.15%
Current year-21.35%
1 week 8.11
Extreme 8.11
9.76
1 month 8.11
Extreme 8.11
16.2
Current year 8.11
Extreme 8.11
43.85
1 year 7.15
Extreme 7.15
43.85
3 years 5.23
Extreme 5.231
61.3
5 years 5.23
Extreme 5.231
237
10 years 5.23
Extreme 5.231
283
Manager TitleAgeSince
Chief Executive Officer 55 13/03/2025
Director of Finance/CFO 53 02/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 70 01/08/2009
Director/Board Member 67 01/02/2017
Director/Board Member 51 25/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
18/9/26 Exercice

Chief Technology Officer

8,845 0.0533%
2/6/26 Exercice

Chief Financial Officer

5,000 0.0302%
4/3/26 Exercice

Chief Administrative Officer

1,627 0.0099%
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%-2.47% - - 151M
Average -0.44%
Weighted average by Cap. -0.44%

Financials

2026 *2027 *
Net sales 52.63M 47.18M 43.42M 39.31M 73.55M 5B 74.87M 517M 208M 2.63B 198M 193M 8.29B 31.23M 27.99M 25.76M 23.32M 43.63M 2.97B 44.42M 306M 123M 1.56B 117M 115M 4.92B
Net income -130M -117M -107M -97.13M -182M -12.35B -185M -1.28B -513M -6.49B -488M -478M -20.49B -143M -128M -118M -107M -200M -13.58B -203M -1.4B -564M -7.14B -537M -525M -22.53B
Net Debt - -
Projected Income Statement - Annual - Sutro Biopharma, Inc.
Logo Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Employees
128
Date Price Change Volume
30/10/26 US$9.100 -0.44% 122,290
29/10/26 US$9.140 -1.61% 260,214
28/10/26 US$9.290 +4.74% 353,523
27/10/26 US$8.870 -0.17% 453,236
26/10/26 US$8.885 -4.77% 694,466
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Sutro Biopharma, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
9.100USD
Average target price
47.23USD
Spread / Average Target
+419.02%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sutro Biopharma, Inc.
  1. Stock Market
  2. Stocks
  3. STRO Stock